3. Dezember 2020 – EMA’s human medicines committee (CHMP) has started a rolling review of Ad26.COV2.S, a COVID-19 vaccine from Janssen-Cilag International N.V. that shall trigger the production of antibodies and immune cells that target the SARS-CoV-2 coronavirus. As soon as enough evidence is available, a formal marketing authorisation application can be filed by Janssen-Cilag International N.V.

For further information, see here.